A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
Recruiting · Phase 1 · NCT06880549
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $474,078
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 42
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-4106 (biological), Pembrolizumab (biological), mRNA-4200 (biological)
- Dates
- Started 2025-03-25; completion 2027-08-03
- Results posted
- Not yet
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $474,078 in research payments for this study in 2025 (36 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Manish Sharma, M.D. Medical Oncology · Grand Rapids, MI
- Amita Patnaik, M.D. Medical Oncology · San Antonio, TX
- William B. Mckean JR., M.D., PH.D. Student in an Organized Health Care Education/Training Program · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- South Texas Accelerated Research Therapeutics LLC $332,983
- South Texas Accelerated $126,414
- Start San Antonio LLC $8,006
- Start Mountain Region LLC $6,676
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.